ABSTRACT
Using a well characterized monoclonal antibody (PR7212) to the beta-subunit of the platelet-derived growth factor receptor (PDGF-R(beta) and the avidin-biotin peroxidase method on frozen sections, we analyzed PDGF-R(beta) expression in 71 nonepithelial lesions as well as normal mesenchymal tissues. PDGF-R(beta) reactivity was observed in normal salivary gland, normal cutaneous and visceral fibroblasts, muscularis mucosa of bowel, and endothelial cells; squamous carcinoma was negative. Interestingly, hepatocytes and lymph node histiocytes were also positive. Positive tumors included malignant fibrous histiocytoma (6/6), benign and malignant smooth muscle tumors (5/6 leiomyoma, 8/9 leiomyosarcoma), liposarcoma (4/4), synovial sarcoma (6/7), angiosarcoma (2/2), and sarcoma NOS (2/2). Fibromatosis cases were also positive (2/2). In many tumors, the reactive fibroblasts and vascular components were also reactive. The characteristic pattern of reactivity in fibroblastic lesions highlighted thin cytoplasmic extensions or strands not visible in normal hematoxylin and eosin-stained sections. Expression of PDGF-R(beta) was not necessarily correlated with the presence of PDGF. We conclude that PDGF-R(beta) expression can be identified in a wide variety of mesenchymal lesions and postulate that its presence may be important in the mechanism of growth of these tumors.
Subject(s)
Receptors, Cell Surface/analysis , Soft Tissue Neoplasms/immunology , Adenocarcinoma/chemistry , Adenocarcinoma/immunology , Adenocarcinoma/ultrastructure , Antibodies, Monoclonal/immunology , Astrocytoma/chemistry , Astrocytoma/immunology , Astrocytoma/ultrastructure , Breast Neoplasms/chemistry , Breast Neoplasms/immunology , Breast Neoplasms/ultrastructure , Cell Transformation, Neoplastic , Fibroblasts/chemistry , Fibroblasts/immunology , Fibroblasts/ultrastructure , Glioma/chemistry , Glioma/immunology , Glioma/ultrastructure , Humans , Immunoenzyme Techniques , Immunohistochemistry/methods , Intestinal Mucosa/chemistry , Intestinal Mucosa/immunology , Intestinal Mucosa/ultrastructure , Leiomyoma/chemistry , Leiomyoma/immunology , Leiomyoma/ultrastructure , Lipoma/chemistry , Lipoma/immunology , Lipoma/ultrastructure , Macromolecular Substances , Osteosarcoma/chemistry , Osteosarcoma/immunology , Osteosarcoma/ultrastructure , Platelet-Derived Growth Factor/analysis , Platelet-Derived Growth Factor/immunology , Platelet-Derived Growth Factor/physiology , Receptors, Cell Surface/immunology , Receptors, Cell Surface/physiology , Receptors, Platelet-Derived Growth Factor , Salivary Glands/chemistry , Salivary Glands/immunology , Salivary Glands/ultrastructure , Sarcoma/chemistry , Sarcoma/immunology , Sarcoma/ultrastructure , Sarcoma, Synovial/chemistry , Sarcoma, Synovial/immunology , Sarcoma, Synovial/ultrastructure , Soft Tissue Neoplasms/chemistry , Soft Tissue Neoplasms/ultrastructureABSTRACT
A retrospective study was performed to determine whether the areae gastricae pattern in the stomach or other radiologic features could be used on double-contrast upper gastrointestinal examinations to accurately diagnose atrophic gastritis in pernicious anemia. The double-contrast studies from 21 patients with pernicious anemia and 55 age-matched controls were interspersed and reviewed blindly to assess gastric size, mucosal folds, and the areae gastricae pattern in the stomach. The best set of criteria for differentiating the pernicious anemia group from the controls included a fundal diameter of 8 cm or less, absent mucosal folds in the fundus or body, and small (i.e., 1-2 mm in size) or absent areae gastricae. This combination of findings was present in 81% of patients with pernicious anemia but it also was present in 11% of the controls, so that atrophic gastritis in pernicious anemia could not be reliably diagnosed on radiologic criteria. Nevertheless, patients with pernicious anemia invariably had small or absent areae gastricae in the stomach, so that the presence of prominent areae gastricae, particularly in the fundus, may be a useful criterion for excluding this disease.
